Context Therapeutics INC

Context Therapeutics Inc. received a notice from Nasdaq for failing to meet the Minimum Bid Price Rule, with 180 days to regain compliance.

Context Therapeutics stockholders approved an increase in authorized common stock from 200 million to 300 million shares.

Context Therapeutics announces encouraging interim Phase 1 data for CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, showing a 29% ORR in platinum-resistant ovarian cancer.

Context Therapeutics has amended its license agreement with BioAtla for CT-202, eliminating future milestone and royalty payments in exchange for a $6.5 million payment and securing irrevocable rights to the bispecific antibody.

Context Therapeutics has finalized the resolution of a stockholder class action lawsuit through a third-party funded mootness fee payment.

Context Therapeutics Inc. updated its corporate presentation, highlighting its T-cell engager pipeline for solid tumors and projecting a cash runway into mid-2027.

Context Therapeutics Inc. reported a net loss of $8.7 million for Q1 2026, with a significant increase in R&D expenses to advance its pipeline, while maintaining a cash runway projected into mid-2027.

Context Therapeutics reports reduced net losses and pipeline progress for its T cell engager bispecific antibodies, extending its cash runway into 2027.

Context Therapeutics reported a wider net loss in Q2 2025 due to increased research and development expenses as it advanced its bispecific antibody pipeline, including CTIM-76 and CT-95, into Phase 1 trials.

Context Therapeutics reports a net loss of $4.6 million for Q1 2025 and highlights progress in clinical trials for its bispecific antibody candidates.

Context Therapeutics reported its third quarter 2024 financial results, highlighting progress in its bispecific antibody programs and a significant increase in cash reserves following a private placement.

Context Therapeutics reported its second quarter 2024 financial results, highlighted by a significant increase in cash reserves following a private placement and advancements in its clinical programs.

Context Therapeutics Inc. reported a net loss of $36.1 million for 2025 as it advanced its bispecific antibody pipeline for solid tumors, with key clinical trial data expected in 2026.

Context Therapeutics Inc. announces its 2024 financial results and provides updates on the clinical development of its T cell engaging bispecific antibody programs targeting solid tumors.

Context Therapeutics Inc.'s 10-K filing outlines the company's share structure, voting rights, and measures designed to deter hostile takeovers.

Director Andy Pasternak of Context Therapeutics Inc. acquired 45,000 stock options with an exercise price of $0.576, vesting on June 24, 2027.

Director Stacey Jennifer Evans acquired stock options in Context Therapeutics Inc. (CNTX) on June 24, 2026, as detailed in a recent SEC Form 4 filing.

Director Linda West acquired 45,000 stock options in Context Therapeutics Inc. (CNTX) with an exercise price of $0.576, vesting on June 24, 2027.

Karen L. Smith, a Director at Context Therapeutics Inc., acquired 45,000 stock options on June 24, 2026, as detailed in a Form 4 filing.

Luke Nathaniel Walker, a Director at Context Therapeutics Inc., acquired 45,000 stock options with an exercise price of $0.576.

Philip Kantoff, a Director at Context Therapeutics Inc., acquired 45,000 stock options with an exercise price of $0.576, vesting on June 24, 2027.

Context Therapeutics Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 24, 2026, and is seeking approval to increase its authorized common stock.

Context Therapeutics Inc. has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.

Context Therapeutics is asking stockholders to approve a reverse stock split to increase its stock price and maintain its Nasdaq listing.

Context Therapeutics Inc. has filed a definitive proxy statement with the SEC.

Context Therapeutics is asking stockholders to approve an amendment to its corporate charter to increase the number of authorized common shares from 100 million to 200 million.

Context Therapeutics Inc. has filed a definitive proxy statement with the SEC.

Octagon Capital Advisors LP, along with affiliated entities and its principal beneficial owner Ting Jia, has reported beneficial ownership of 3.3% of Context Therapeutics Inc. common stock.

BlackRock, Inc. has reported a beneficial ownership of 6.7% in Context Therapeutics Inc. common stock as of June 30, 2026.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D. and Ms. Lillian Nordahl, has reported beneficial ownership of 2,238,496 shares, representing 2.44% of Context Therapeutics Inc.'s common stock as of March 31, 2026.

Blue Owl Capital Holdings LP has filed a Schedule 13G, reporting beneficial ownership of 5,089,015 shares, representing 5.54% of Context Therapeutics Inc.'s common stock as of March 31, 2026.

Octagon Capital Advisors LP, along with its affiliates, has disclosed beneficial ownership of 5,250,000 shares, representing 5.7% of Context Therapeutics Inc.'s common stock.

Avidity Partners Management LP and affiliated entities have amended their Schedule 13G filing, reporting beneficial ownership of 8,302,808 shares of Context Therapeutics Inc. common stock, representing 8.7% of the class.